• C57BL6 Chronic MOG_(35-55) Model – this model shows a continual increase in severity of symptoms and can be described as primary progressive.

• SJL/J PLP+PTX Model – this model can be used as an acute or a chronic model. Clinical scores are not as severe as in the MOG(35-55) model and are not progressive. There is a complete relapsing and remitting pattern.

• SJL/J PLP Model – this model also shows a relapsing and remitting patter but clinical scores are higher than in the SJL/J PLP+PTX model and the pattern of relapsing and remission exists markedly but there is no return to baseline.

More information on these models as well as the other tools Cerebricon can provide for the study of MS can be found by linking to our Revised MS white paper that can be found in the Resources Section on the Cerebricon web site:

http://www.cerebricon.com/DowebEasyCMS/?Page=Resources

In response to the completion of the internal validation of these models Cerebricon Head of Models Development Antti Nurmi stated, “The team is particularly happy with the results of the in-house validations. It has been our thinking for some time that it is simply not good enough to deliver a single model to use as a tool to study compounds aimed at a particular disease. Therefore, to be able to deliver three different mouse models and couple these with our existing rat models we can now claim to have the most complete suite of in vivo models for MS. In subsequent months we will release an in vitro component in the form of a myelin assay in order to further compliment this particular in vivo platform.”

For more information please contact Cerebricon Ltd. info@cerebricon.com.

About Multiple Sclerosis (MS):
MS is a disease caused by an autoimmune attack against the isolating axonal myelin sheaths of the central nervous system (CNS). This often results in severe disability although there can be periods of remission. MS currently affects around 2.5 million people worldwide and can start at a young age i.e. between the ages of 20 and 40.

About Cerebricon Ltd.:
Cerebricon Ltd. is a collaborative and contract research organization, specializing in Preclinical models of CNS and PNS diseases for drug discovery and pharmacological research. Located in Kuopio, Finland with sales and marketing offices in London, UK and Los Angeles, USA. Cerebricon serves small, medium and large pharmaceutical companies as well as independent researchers and academic institutions around the globe. Cerebricon Ltd. is a completely privately owned company with fully proprietal staff and laboratories.